Table 1.
Patient Characteristics
| Controls (n=10) | All CA Patients (n=25) | P Value | |
|---|---|---|---|
| Male, % | 30 | 80 | <0.01 |
| BMI, kg/m2 | 26±4 | 25±3 | 0.30 |
| BSA, m2 | 2.0±0.2 | 1.9±0.2 | 0.45 |
| Age, y | 64 [62–66] | 69 [55–78] | 0.27 |
| NYHA functional class >I, % | 0 | 68 | <0.001 |
| Hypertension, % | 0 | 24 | 0.09 |
| Medication | |||
| Statins, % | 0 | 20 | 0.13 |
| ACE/Angiotensin II inhibitor, % | 0 | 24 | 0.09 |
| Beta blockers, % | 0 | 28 | 0.06 |
| Furosemide or bumetanide, % | 0 | 64 | 0.001 |
| Thiazide, % | 0 | 8 | 0.36 |
| Spironolactone, % | 0 | 16 | 0.18 |
| Biochemistry | |||
| Creatinine, μmol/L | 84 [72–92] | 106 [83–134] | <0.05 |
| Hemoglobin, mmol/L | 8.7±0.6 | 8.4±1.0 | 0.33 |
| NT‐ProBNP, ng/L | 33 [27–74] | 1962 [674–4268] | <0.0001 |
Data are presented as absolute number and present or mean±SD or median and interquartile range. ACE indicates acetylcholinesterase; BMI, body mass index; BSA, body surface area; NT‐ProBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association.